Viva Biotech Holdings Balance Sheet Health
Financial Health criteria checks 3/6
Viva Biotech Holdings has a total shareholder equity of CN¥3.7B and total debt of CN¥1.9B, which brings its debt-to-equity ratio to 50.7%. Its total assets and total liabilities are CN¥7.4B and CN¥3.8B respectively. Viva Biotech Holdings's EBIT is CN¥192.7M making its interest coverage ratio 1.3. It has cash and short-term investments of CN¥1.0B.
Key information
50.7%
Debt to equity ratio
CN¥1.87b
Debt
| Interest coverage ratio | 1.3x |
| Cash | CN¥1.04b |
| Equity | CN¥3.69b |
| Total liabilities | CN¥3.76b |
| Total assets | CN¥7.45b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: VB0's short term assets (CN¥2.0B) exceed its short term liabilities (CN¥1.5B).
Long Term Liabilities: VB0's short term assets (CN¥2.0B) do not cover its long term liabilities (CN¥2.2B).
Debt to Equity History and Analysis
Debt Level: VB0's net debt to equity ratio (22.6%) is considered satisfactory.
Reducing Debt: VB0's debt to equity ratio has reduced from 88.7% to 50.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if VB0 has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if VB0 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.